Leidos Holdings enters its May 5 earnings call in an uncomfortable spot — the stock has shed 6% over the past month to close at $145.91, and every analyst move in the past two weeks has been a price-target cut, even as the Street kept its buy ratings intact.
The Street's message has been consistent but downbeat. BofA Securities trimmed its target from $235 to $200 on April 21, while maintaining a Buy, and Truist Securities followed a day earlier with a cut from $220 to $195, also keeping Buy. Both are recent enough to matter and point to the same thing: analysts still like the name, but they are revising down what they think it is worth. Wells Fargo initiated coverage on April 1 with an Equal-Weight and a $165 target — well below the group consensus of roughly $199 — putting a soft ceiling on Street enthusiasm. The mean target still implies about 37% upside from here, but that gap has more to do with where the stock has fallen than with the Street ratcheting up its ambitions. The RSI-14 has dropped to a deeply oversold 31.8, and the stock is down nearly 20% year-to-date, meaning much of the damage from the broader defense-spending anxiety has already landed on the price.
The positioning data tells a less charged story than the price might suggest. Short interest is modest at 2.8% of the free float, and it actually fell around 5.6% over the past week, reversing a build that had run through mid-April. Days to cover are just 1.2, meaning shorts carry little conviction and could unwind quickly. Borrow costs are negligible at 0.37% — down 5% on the week — and availability remains loose, with utilization well below historical highs. The 52-week peak utilization was just 5.5%, compared to roughly 1.4% now. There is no meaningful squeeze pressure or forced-cover dynamic in the lending market heading into earnings. Options positioning is slightly more defensive than normal — the put/call ratio edged up to 0.66, about one standard deviation above its 20-day mean of 0.60 — but nowhere near the extreme readings the stock has seen in the past year, when the PCR touched 1.40.
The bull and bear cases ahead of May 5 revolve around the same fault line: contract execution and segment mix. Bulls point to Leidos' positioning in defense technology and energy as longer-term growth levers, and see a path to margin improvement in 2027. Bears flag the managed health services drag — volumes in the Health segment are declining, creating a margin headwind that is unlikely to reverse quickly — and question whether the company's push into new markets through acquisitions creates more uncertainty than it resolves. Valuation has compressed meaningfully: the P/E multiple has contracted by one full turn over the past 30 days to roughly 11.6x, and EV/EBITDA slipped by about 0.4x to 9.0x. At these levels, the stock trades at a discount to where it spent most of the past year, reflecting the combination of softer government IT spending sentiment and the Health segment noise.
Among close peers, FCN fell 3.2% on the week and PSN dropped 6.3%, suggesting the pressure on Leidos is sector-wide rather than company-specific. SAIC and BAH held in relatively better, each off less than 1.5% over the same period. That divergence hints at some selectivity emerging within defense services, with investors rotating toward names less exposed to discretionary government consulting work.
The last quarterly print in February produced a 2.7% one-day decline. The quarter before that was far worse — an 11% drop on the day. Whether the pattern repeats or breaks on May 5 depends largely on whether management can demonstrate that the Health segment headwind is contained and that the contract pipeline holds. That's the number to watch.
See the live data behind this article on ORTEX.
Open LDOS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
